New Data Presented at ESTRO 2022 Reinforces Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities


More than 70 abstracts draw on the clinical evidence supporting the use of these technologies

SUNNYVALE, Calif., May 10, 2022 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) today announced that clinical studies continue to validate the versatility of the company’s CyberKnife® and TomoTherapy® platforms, including the next-generation Radixact® System, for treating precision and efficiency a wide variety of indications of all complexities. Data presented at the European Society for Radiotherapy and Oncology (ESTRO) Annual Congress 2022 held in Copenhagen, Denmark demonstrate how advanced radiotherapy platforms enable medical care teams to provide truly personalized care aligned with the needs of each patient.

“Accuray was founded to provide clinicians with technology that delivers ultra-precise radiation therapy treatments and advances the care of patients diagnosed with cancer or neurological disorders. The data shared at ESTRO shows that our customers are making that aspiration a reality and increasing the impact they have by using our cutting-edge technologies,” said Suzanne WinterPresident of Accuray.

Ms. Winter added, “We are committed to being the recognized leader in radiation therapy innovation by continuing to invest in technologies that offer new and effective ways to treat medical conditions that can benefit from this type of treatment and expand the care options available. At this year’s ESTRO, we’re proud to highlight advances in our partnership with C-RAD, for example, which are designed to provide customers with a solution for the Radixact system that will position it as the ideal system for the entire range. breast cancer indications, which account for up to 25% of radiotherapy patient cases.

New data presented at ESTRO
CyberKnife platform’s unique robotic technology, non-coplanar and Synchrony beam delivery® The technology enables more anatomical sites to be treated with ultra-hypofractionated radiation therapy, helping to make a clinical difference for patients every day.

  • Neurological disorders: Sub-millimeter precision allows stereotactic radiosurgery (SRS) to be delivered to a diverse patient population. Studies indicate that CyberKnife SRS can:
    • Increase the survival of patients with recurrent high-grade gliomas.
    • To offer patients with acoustic neuromas an effective and well-tolerated treatment with excellent tumor control and acceptable hearing preservation.
    • Provide good local control with low toxicity when treating HER2 breast cancer brain metastases.
  • Breast Cancer: Several studies show that the CyberKnife System with Synchrony can provide promising results in early stage patients. Studies evaluating the system found:
    • Single-dose preoperative radiotherapy is a feasible and well-tolerated technique with a promising response rate.
    • Stereotactic accelerated partial breast irradiation (S-APBI) in four fractions after lumpectomy is a feasible and reproducible technique. The treatment was well tolerated and the aesthetic results were rated as good or excellent by all patients.
    • S-APBI in five fractions after lumpectomy is well tolerated.

tomotherapy® The platform pioneered the use of helical radiation delivery and integrated imaging, providing better control of radiation dose to precisely conform to the tumor and allowing delivery from conventionally fractionated to ultra-hypofractionated treatments.

  • Innovative Techniques: Accurate and efficient radiation dose delivery enables a wide range of patients to receive treatment, including those with complex indications. Studies conducted with TomoHelical™ Treatment Delivery demonstrate:
    • Total marrow irradiation in combination with tandem autologous transplantation may provide favorable long-term (10 years) outcomes and toxicity in patients with multiple myeloma.
    • Simultaneous integrated boost and intensity modulated radiation therapy (IMRT) may offer favorable results and acceptable toxicity in the treatment of anal cancer.
    • The combination of IMRT and high dose rate intracavitary brachytherapy can provide excellent local control and favorable overall survival for patients with non-metastatic cervical cancer.
    • Single fraction lumbopelvic bone irradiation is a promising and highly effective treatment option with excellent tolerance rates for patients with multiple painful bone metastases.

Important Safety Information
For important safety information, please see

About Accuray
Accuray is committed to unlocking the powerful potential of radiation therapy to improve as many lives as possible. We invent unique and revolutionary solutions designed to provide radiation treatment for even the most complex cases, while making commonly treatable cases even easier, to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery and beyond, in partnership with clinicians and administrators, enabling them to help patients get back to life faster. Accuray is headquartered in Sunnyvale, California, with installations around the world. To learn more, visit or follow us on Facebook, LinkedIn, Twitterand YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this press release relate to, but are not limited to, planned investments in technology, new products and innovations, clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. Should one of these risks or uncertainties materialize, or should any of the company’s assumptions prove incorrect, actual results could differ materially from the results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the COVID-19 pandemic on the company’s operations and those of its customers and suppliers, the company’s ability to obtain widespread acceptance of its products by the market; the company’s ability to develop new products or improve existing products to meet customer needs; the company’s ability to anticipate or keep pace with changes in the market and the direction of technological innovation and customer demands and other risks identified under “Risk Factors” in the company’s quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2022and periodically updated with other filings by the company with the SEC.

Forward-looking statements speak only as of the date they are made and are based on information available to the company at the time such statements are made and/or the good faith belief of management at that time. regarding future events. The company undertakes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions, or changes in other factors affecting the forward-looking information, except to the extent required by applicable laws. applicable securities. Accordingly, investors should not place undue reliance on forward-looking statements.

Media Contact
Beth Kaplan
Director of Public Relations, Accuray
+1 (408) 789-4426
[email protected]

SOURCE Accuray Incorporated


Comments are closed.